Klinomics Signs MOU with Humancellbio for Stem Cell and Immune Cell Therapy Development

Clinomics announced on the 27th that it has signed a memorandum of understanding (MOU) for joint research and technology development, including the development of 'immune cell therapies using mitochondria,' with HumanCellBio, a specialized company in advanced biopharmaceutical development.

A Clinomics representative stated, "HumanCellBio is an advanced biopharmaceutical development company possessing technology for immune response regulation, anti-aging, and disease treatment utilizing mitochondria." Mitochondria are the most important cellular organelles that produce the energy necessary for human cellular activities, acting as the powerhouse of living organisms.

Clinomics revealed that through this MOU with HumanCellBio, it plans to attempt product development that leverages the synergy between the genome field and cell therapy field. Initially, they will conduct long-term joint research and development of stem cell therapies, immune cell therapies, and NK cell therapies utilizing mitochondria, measure their effects using Genome 2.0 technology, and establish a cycle of continuous improvement to create related products effective against severe diseases and extreme aging.

A company representative said, "Through this joint research and development MOU, Clinomics will promote its clinic business aimed at providing anti-aging specialized services that predict individual health status more accurately based on Genome 2.0 technology, which surpasses the limitations of existing Genome 1.0-based genetic testing, reflecting each individual's health condition." They added, "This is part of Clinomics' founding vision to develop products that encompass not only diagnosis but also treatment in the long term."

This content was produced with the assistance of AI translation services.